Share on StockTwits

DexCom (NASDAQ:DXCM) Director Jay S. Skyler sold 60,000 shares of the company’s stock on the open market in a transaction dated Friday, June 20th. The shares were sold at an average price of $40.00, for a total value of $2,400,000.00. Following the sale, the director now directly owns 6,887 shares of the company’s stock, valued at approximately $275,480. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $33.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $39.80.

DexCom (NASDAQ:DXCM) traded down 0.22% during mid-day trading on Monday, hitting $40.91. The stock had a trading volume of 788,399 shares. DexCom has a 1-year low of $21.65 and a 1-year high of $49.83. The stock’s 50-day moving average is $34.47 and its 200-day moving average is $37.77. The company’s market cap is $3.065 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, May 1st. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.33 earnings per share for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.